Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness
Conclusions (2 of 2)
Triple-therapy regimens were associated with an increased risk of certain harms, particularly hematological events with boceprevir and anemia and rash with telaprevir.
- In studies comparing triple therapy with boceprevir for 48 weeks with dual therapy for 48 weeks, the incidence of anemia was about 50 percent and the incidence of neutropenia was 25 percent in patients receiving triple therapy.
- In studies comparing triple therapy with telaprevir for 24 weeks with dual therapy for 48 weeks, the incidence of anemia was about 27–91 percent and the incidence of neutropenia was 33–66 percent in patients receiving triple therapy.
Achieving a sustained virologic response (SVR) after antiviral therapy appears to be associated with a decreased risk of all-cause mortality when compared with no SVR. The evidence for this finding came mainly from a large, good-quality U.S. Department of Veterans Affairs (VA) cohort study. Although the results of 18 other cohort studies were consistent with the results of the VA study, the studies were small and had methodological shortcomings.
- Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults: A Comparative Effectiveness Review. Evidence Report No. 76 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC113-EF. Available at www.effectivehealthcare.ahrq.gov/hepctreatment.cfm.
Your slide tray is being processed.